Omega Therapeutics, Inc. (OMGA)
NASDAQ: OMGA · IEX Real-Time Price · USD
2.410
+0.030 (1.26%)
At close: May 17, 2024, 4:00 PM
2.480
+0.070 (2.90%)
After-hours: May 17, 2024, 7:51 PM EDT
Omega Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Omega Therapeutics stock have an average target of 10, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 314.94% from the current stock price of 2.41.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for OMGA stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +397.93% | May 13, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +190.46% | May 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +397.93% | Apr 30, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $10 → $9 | Buy | Reiterates | $10 → $9 | +273.44% | Apr 3, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $7 | Strong Buy | Maintains | $12 → $7 | +190.46% | Apr 1, 2024 |
Financial Forecast
Revenue This Year
4.12M
from 3.09M
Increased by 33.19%
Revenue Next Year
816.00K
from 4.12M
Decreased by -80.20%
EPS This Year
-1.17
from -1.80
EPS Next Year
-1.24
from -1.17
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 13.7M | 4.2M | n/a | 59.6M | 524.1M |
| Avg | 4.1M | 816,000 | n/a | 30.6M | 272.2M |
| Low | n/a | n/a | n/a | 3.2M | 33.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 341.2% | 1.9% | - | - | 1,610.8% |
| Avg | 33.2% | -80.2% | - | - | 788.6% |
| Low | - | - | - | - | 10.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.93 | -0.82 | -0.84 | -0.58 | 1.86 |
| Avg | -1.17 | -1.24 | -0.82 | -0.56 | 1.81 |
| Low | -1.48 | -1.75 | -0.78 | -0.54 | 1.73 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.